Skip to main content
SpringerLink
Log in

Pegylated Interferon-α2a and Ribavirin versus Pegylated Interferon-α2b and Ribavirin in Chronic Hepatitis C

A Meta-Analysis

  • Systematic Review
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Introduction

Results of trials and meta-analyses comparing pegylated interferon (PEG-IFN)-α2a and PEG-IFN-α2b for the treatment of chronic hepatitis C are conflicting.

Objective

Our objective was to determine which PEG-IFN (α2a or α2b), in association with ribavirin, is the most effective for the treatment of chronic hepatitis C by performing an updated meta-analysis.

Method

MEDLINE (1950–2012) and EMBASE (1974–2012) databases, as well as the Cochrane Central Register of controlled trials and the Cochrane Database of Systematic Reviews, were searched. Reference lists of retrieved articles were scanned, and proceedings of major international conferences were manually searched for abstracts. Randomized clinical trials and non-randomized clinical studies comparing PEG-IFN-α2a with PEG-IFN-α2b in association with ribavirin in adult patients with chronic hepatitis C were included. Studies including HIV-positive patients or liver transplant recipients were excluded. The data extraction from each study was conducted independently by two authors, with disagreements resolved by consensus or by a third reviewer. The trial quality of randomized clinical trials was assessed by taking into account generation of allocation sequence, allocation concealment, efficacy of randomization, investigator blindness, description of withdrawals and dropouts and adherence to the intention-to-treat principle. Two meta-analyses were performed, the first including randomized clinical trials only, and the second including both randomized and non-randomized clinical studies. The primary outcome measure was frequency of sustained virological response (SVR). Heterogeneity and publication bias were systematically taken into account.

Results

This meta-analysis included 26 studies, 11 randomized and 15 non-randomized, with a total of 18,260 patients: 8,125 treated with PEG-IFN-α2a and 10,135 treated with PEG-IFN-α2b. In the meta-analysis that included randomized trials only, the SVR was significantly higher for patients treated with PEG-IFN-α2a than for those treated with PEG-IFN-α2b for genotypes 1 and 4 [odds ratio (OR) 1.45; 95 % CI 1.09–2.06; p = 0.013] and for all genotypes (OR 1.34; 95 % CI 1.05–1.72; p = 0.02). In the meta-analysis including both randomized and non-randomized studies, the SVR was significantly higher for PEG-IFN-α2a than for PEG-IFN-α2b for all genotypes (OR 1.24; 95 % CI 1.10–1.40; p < 0.001) and for genotypes 1 and 4 (OR 1.25; 95 % CI 1.14–1.36; p < 0.001); for genotypes 2 and 3, the SVR was greater for treatment with PEG-IFN-α2a than with PEG-IFN-α2b, with the difference tending towards significance (OR 1.15; 95 % CI 0.98–1.35; p = 0.08). A certain degree of heterogeneity was present amongst the various studies included in this meta-analysis. Publication bias was detected (particularly for analyses including only randomized controlled trials) and taken into account using appropriate statistical methods.

Conclusion

Current evidence suggests that PEG-IFN-α2a and ribavirin is associated with a higher SVR than PEG-IFN-α2b and ribavirin in patients mono-infected with hepatitis C, particularly for genotypes 1 and 4.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

References

  1. Strader DB, Wright T, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39(4):1147–71.

    Article  PubMed  Google Scholar 

  2. Rumi MG, Aghemo A, Prati GM, et al. Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology. 2010;138(1):108–15.

    Article  PubMed  CAS  Google Scholar 

  3. Ascione A, De Luca M, Tartaglione MT, et al. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology. 2010;138(1):116–22.

    Article  PubMed  CAS  Google Scholar 

  4. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361(6):580–93.

    Article  PubMed  CAS  Google Scholar 

  5. Witthoeft T, Hueppe D, John C, et al. Efficacy and tolerability of peginterferon alfa-2a or alfa-2b plus ribavirin in the daily routine treatment of patients with chronic hepatitis C in Germany: the PRACTICE study. J Viral Hepat. 2010;17(7):459–68.

    PubMed  CAS  Google Scholar 

  6. Craxi A, Piccinino F, Alberti A. Predictors of SVR in naive HCV G1 patients in real life practice: the PROBE. J Hepatol. 2008;44(Suppl 2):S291.

    Article  Google Scholar 

  7. Thuy PT, Dat HT. Comparison between the two PEG interferons alfa in the treatment of chronic hepatitis C. Hepatology. 2007;46(4):387A.

    Google Scholar 

  8. Higgins J, Thompson S, Deeks J, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60.

    Article  PubMed  Google Scholar 

  9. Almasio P, Cavalletto L, Chemello L, et al. Predictors of SVR in genotype 1 patients with treatment-naïve chronic HCV treated with PEG-IFN alfa-2b vs. PEG-IFN alfa-2a+ ribavirin: a hierarchical linear regression analysis of retrospective data from 6 clinic sites. Gastroenterology. 2006;130(4):A842.

    Google Scholar 

  10. Awad T, Thorlund K, Hauser G, et al. Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials. Hepatology. 2010;51(4):1176–84.

    Article  PubMed  CAS  Google Scholar 

  11. Zhao S, Liu E, Chen P, et al. A comparison of peginterferon alpha-2a and alpha-2b for treatment-naive patients with chronic hepatitis C virus: a meta-analysis of randomized trials. Clin Ther. 2010;32(9):1565–77.

    Article  PubMed  CAS  Google Scholar 

  12. Singal AK, Jampana SC, Anand BS. Peginterferon alfa-2a is superior to peginterferon alfa-2b in the treatment of naive patients with hepatitis C virus infection: meta-analysis of randomized controlled trials. Dig Dis Sci. 2011;56(8):2221–6.

    Article  PubMed  CAS  Google Scholar 

  13. Druyts E, Mills EJ, Nachega J, et al. Differences in clinical outcomes among hepatitis C genotype 1-infected patients treated with peginterferon alpha-2a or peginterferon alpha-2b plus ribavirin: a meta-analysis. Clin Exp Gastroenterol. 2012;5:11–21.

    PubMed  CAS  Google Scholar 

  14. Banares R, Albillos A, Rincon D, et al. Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: a meta-analysis. Hepatology. 2002;35(3):609–15.

    Article  PubMed  Google Scholar 

  15. Juni P, Altman DG, Egger M. Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ. 2001;323(7303):42–6.

    Article  PubMed  CAS  Google Scholar 

  16. Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27(5):335–71.

    Article  PubMed  CAS  Google Scholar 

  17. Breslow NE, Day NE. Statistical methods in cancer research. Volume I: the analysis of case-control studies. Lyon: International Agency for Research on Cancer; 1980.

    Google Scholar 

  18. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.

    Article  PubMed  CAS  Google Scholar 

  19. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.

    Article  PubMed  Google Scholar 

  20. Egger M, Smith GD, Phillips AN. Meta-analysis: principles and procedures. BMJ. 1997;315(7121):1533–7.

    Article  PubMed  CAS  Google Scholar 

  21. Orwin R. A fail-safe N for effect size in meta-analysis. J Educ Behav Stat. 1983;8(2):157–9.

    Article  Google Scholar 

  22. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56(2):455–63.

    Article  PubMed  CAS  Google Scholar 

  23. Marcellin P, Forns X, Goeser T. Virological analysis of patients receiving telaprevir administered Q8h or Q12h with peginterferon-alfa-2a or -alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C: study C208 (abstract no. 194). Hepatology. 2009;50(Suppl 4):395A.

    Google Scholar 

  24. Forns X, Marcellin P, Ferenci P. On-treatment response-guided therapy with telaprevir q8 h or q12 h combined with peginterferon alfa-2a or peginterferon alfa-2b and ribavirin in treatment-naive genotype 1 hepatitis C (Study C208). J Hepatol. 2010;52:S109–10.

    Article  Google Scholar 

  25. Chou R, Carson S, Chan BK. Pegylated interferons for chronic hepatitis C virus infection: an indirect analysis of randomized trials. J Viral Hepat. 2008;15:551–70.

    Article  PubMed  CAS  Google Scholar 

  26. Silva M, Poo J, Wagner F, et al. A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE). J Hepatol. 2006;45(2):204–13.

    Article  PubMed  CAS  Google Scholar 

  27. Foster GR. Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b. Drugs. 2010;70(2):147–65.

    Article  PubMed  CAS  Google Scholar 

  28. Laguno M, Cifuentes C, Murillas J, et al. Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology. 2009;49(1):22–31.

    Article  PubMed  CAS  Google Scholar 

  29. Berenguer J, Gonzalez-Garcia J, Lopez-Aldeguer J, et al. Pegylated interferon alpha 2a plus ribavirin versus pegylated interferon alpha 2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. J Antimicrob Chemother. 2009;63(6):1256–63.

    Article  PubMed  CAS  Google Scholar 

  30. Crespo M, Mira JA, Pineda JA, et al. Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen. J Antimicrob Chemother. 2008;62(4):793–6.

    Article  PubMed  CAS  Google Scholar 

  31. Fumaz CR, Munoz-Moreno JA, Ballesteros AL, et al. Influence of the type of pegylated interferon on the onset of depressive and neuropsychiatric symptoms in HIV-HCV coinfected patients. AIDS Care. 2007;19(1):138–45.

    Article  PubMed  CAS  Google Scholar 

  32. Vispo E, Barreiro P, Rodriguez-Novoa S, et al. Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b. Antivir Ther. 2008;13(4):511–7.

    PubMed  CAS  Google Scholar 

  33. Berak H, Horban A, Wasilewski M, et al. Randomized, open label trial comparing efficacy and safety of pegylated interferon alfa 2A vs alfa 2B treatment of patients with chronic hepatitis C infected with non 2/3 genotypes: 12 week virological response analysis. Hepatology. 2005;42(S1):684A.

    Google Scholar 

  34. Bruno R, Sacchi P, Ciappina V, et al. Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis C: a randomized, controlled study. Antivir Ther. 2004;9(4):491–7.

    PubMed  CAS  Google Scholar 

  35. Di Bisceglie AM, Ghalib RH, Hamzeh FM, et al. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C. J Viral Hepat. 2007;14(10):721–9.

    PubMed  Google Scholar 

  36. Hassanein T, Ye X, Blumentals W. Clinical and persistency outcomes in hepatitis C patients treated with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin. J Hepatol. 2008;48:S295–6.

    Article  Google Scholar 

  37. Bruno R, Sacchi P, Scagnolari C, et al. Pharmacodynamics of peginterferon alpha-2a and peginterferon alpha-2b in interferon-naive patients with chronic hepatitis C: a randomized, controlled study. Aliment Pharmacol Ther. 2007;26(3):369–76.

    Article  PubMed  CAS  Google Scholar 

  38. Webb A, Poy I, Patel R, et al. Comparison of ribavirin with PEG-interferon alpha-2a with alpha-2b in treatment-naive patients. Am J Gastroenterol. 2006;101(9):S285–6.

    Google Scholar 

  39. Anees R, Reddymasu S, Bejjanki H, et al. Pegyled-interferon alpha-2a (Pegasys) versus pegyled-interferon alpha-2b (Pegintron) in the treatment of chronic hepatitis C infection. Am J Gastroenterol. 2005;100(9):S142.

    Google Scholar 

  40. Kamal S, Ghoraba D, Nabegh L, et al. Pegylated interferon alfa-2a vs pegylated interferon alfa-2b, plus ribavirin, for chronic hepatitis C genotype 4 patients: a randomized controlled trial. Hepatology. 2009;50(S4):1025A–6A.

    Google Scholar 

  41. Scotto G, Fazio V, Fornabaio C, et al. Early and sustained virological response in non-responders with chronic hepatitis C: a randomized open-label study of pegylated interferon-alpha-2a versus pegylated interferon-alpha-2b. Drugs. 2008;68(6):791–801.

    Article  PubMed  CAS  Google Scholar 

  42. Scotto G, Fazio V, Fornabaio C, et al. Peg-interferon alpha-2a versus Peg-interferon alpha-2b in nonresponders with HCV active chronic hepatitis: a pilot study. J Interf Cytokine Res. 2008;28(10):623–9.

    Article  CAS  Google Scholar 

  43. Berak A, Kołakowska-Rządzka A, Wasilewski M. Randomized, open label trial comparing efficacy and safety of pegylated interferon alfa 2a vs alfa 2b treatment of patients with chronic hepatitis C infected with non 2/3 genotypes: final analysis. J Hepatol. 2007;46:S217–8.

    Article  Google Scholar 

  44. Stipho S, Rodriguez-Luna H, Tharalson E, et al. Relapse and non-response rates with pegylated interferon (PEG-IFN) alfa 2a and 2b in the treatment of veterans with chronic hepatitis C. Am J Gastroenterol. 2006;101(9):416.

    Google Scholar 

  45. Kim JI, Kim SH, Lee BS, et al. Efficacy of initial treatment with peginterferon alpha-2a versus peginterferon alpha-2b in combination with ribavirin in naive chronic hepatitis C patients living in Daejeon and Chungcheong Province in Korea: a comparative study. Korean J Hepatol. 2008;14(4):493–502.

    Article  PubMed  Google Scholar 

  46. Kolakowska A, Berak H, Wasilewski M, et al. Relevance between fibrosis and response to treatment with peginterferon alfa2a vs alfa2b with ribavirin in chronic hepatitis C genotype 3 patients: randomized open label study. Hepatology. 2008;48:1278.

    Google Scholar 

  47. Sinha S, Gulur P, Patel V, et al. A randomized prospective clinical trial comparing pegylated interferon alpha 2a/ribavirin versus pegylated interferon alpha 2b/ribavirin in the treatment of chronic hepatitis C. Am J Gastroenterol. 2004;99:237.

    Google Scholar 

  48. Yenice N, Mehtap O, Gumrah M, et al. The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients. Turk J Gastroenterol. 2006;17(2):94–8.

    PubMed  Google Scholar 

  49. Magni C, Niero F, Argenteri B. Antiviral activity and tolerability between pegyled interferon alpha-2a and alpha-2b in naive patients with chronic hepatitis C: results of prospective monocentric randomized trial. Hepatology. 2009;50(Suppl 4):720A.

    Google Scholar 

  50. Khan AQ, Awan A, Shahbuddin S, et al. Peginterferon alfa 2a/ribavirin versus peginterferon alfa 2b/ribavirin combination therapy in chronic hepatitis C genotype 3. Gastroenterology. 2007;132(4):A200.

    Google Scholar 

  51. Miyase S, Haraoka K, Ouchida Y, et al. Randomized trial of peginterferon alpha-2a plus ribavirin versus peginterferon alpha-2b plus ribavirin for chronic hepatitis C in Japanese patients. J Gastroenterol. 2012;47(9):1014–21.

    Article  PubMed  CAS  Google Scholar 

  52. Backus LI, Boothroyd DB, Phillips BR, et al. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology. 2007;46(1):37–47.

    Article  PubMed  CAS  Google Scholar 

  53. Cozzolongo R, Sartorie M, Lanzilotta E, et al. Comparison between the two peginterferons alpha in the treatment of chronic hepatitis C. J Hepatol. 2006;44(Suppl. 2):S209.

    Article  Google Scholar 

  54. Escudero A, Rodriguez F, Serra MA, et al. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study. J Gastroenterol Hepatol. 2008;23(6):861–6.

    Article  PubMed  CAS  Google Scholar 

  55. Hammoud I, Sherbondy M, Moonka D. Peginterferon alpha-2b versus peginterferon alpha-2a in the treatment of chronic hepatitis C infection. Hepatology. 2007;46(Suppl. 1):386A–7A.

    Google Scholar 

  56. Mauss S, Berger F, Felton G, et al. Peginterferon alpha-2a versus peginteferon alpha-2b in the treatment of chronic hepatitis C. J Hepatol. 2005;42(Suppl. 2):213.

    Google Scholar 

  57. Terreni N, Andreoletti M, Borroni G, et al. Retrospective analysis of the efficacy of PEG-IFN alpha 2A vs PEG-IFN alpha 2A plus ribavirin in treatment naïve chronic HCV patients. Dig Liv Dis. 2009;41(Suppl. 1):S113.

    Article  Google Scholar 

  58. Moore C, Angtuaco T, Lindsey J, et al. No difference in efficacy and tolerability between pegylated interferon alfa-2a vs. alfa-2b in combination with ribavirin in treatment of naïve patients with chronic hepatitis C. Am J Gastroenterol. 2005;100(9):262.

    Google Scholar 

  59. Lee S, Kim I, Kim S. Efficacy and tolerability of pegyled interferon alpha 2a plus ribavirin versus pegyled interferon alpha 2b plus ribavirin in treatment-naive chronic hepatitis C patients. Intervirology. 2010;53:146–53.

    Article  PubMed  CAS  Google Scholar 

  60. Jeong J, Lee JW, Lee JI, et al. Comparison to efficacy and tolerability of peginterferon alfa-2a or alfa-2b plus ribavirin in the treatment of chronic hepatitis C (CHC) in Korea: in Kyeonggi-Incheon Province, Peginterferon effects on CHC treatment (KIPECT) study. Hepatology. 2011;54(Suppl 1):850A.

    Google Scholar 

  61. Villa E, Camma C, Di Leo A, et al. Peginterferon-alpha_2B plus ribavirin is more effective than peginterferon-alpha_2A plus ribavirin in menopausal women with chronic hepatitis C. J Viral Hepat. 2012;19(9):640–9.

    Article  PubMed  CAS  Google Scholar 

  62. Thompson AJ, Muir AJ, Sulkowski, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010;139(1):120–129.e18.

    Article  PubMed  CAS  Google Scholar 

  63. Gellad ZF, Naggie S, Reed SD, et al. The cost-effectiveness of a telaprevir-inclusive regimen as initial therapy for genotype 1 hepatitis C infection in individuals with the CC IL-28B polymorphism (abstract no. 118). Hepatology. 2011;54(4 Suppl):417A.

    Google Scholar 

  64. Martinot-Peignoux M, Christianne S, Leclere L, et al. Assessment of serum HCV RNA at week 12 post treatment is as relevant as week 24 to predict SVR in patients with chronic hepatitis C treated with pegylated interferon plus ribavirin. Hepatology. 2009;50(4):359A.

    Google Scholar 

  65. Flamm S, Goldman J, Cahan J, et al. PEG-IFN alpha 2b (1.5 μg/kg/wk) + Rib (800–1400 mg daily) is more effective than PEG-IFN alpha 2B (1 μg/kg/wk) + Rib (800–1400 mg daily) in men with GT 1 and women with GT 2/3: final results of a prospective, randomized, controlled trial. Hepatology. 2005;42(4):669A.

    Google Scholar 

Download references

Acknowledgments

The authors have no conflicts of interests to report. This meta-analysis was neither funded nor sponsored by any pharmaceutical company. Nicolas Flori and Natalie Funakoshi contributed equally to this study.

Author information

Authors and Affiliations

  1. Service d’Hépato-gastroentérologie B, Hôpital Saint Eloi, CHU Montpellier, 80 rue Augustin Fliche, 34295, Montpellier Cedex 5, France

    Nicolas Flori, Natalie Funakoshi, Jean-Christophe Valats, Michael Bismuth, Dimitri Christophorou & Pierre Blanc

  2. Département d’Information Médicale, CHU Nîmes, Nîmes, France

    Yohan Duny & Jean-Pierre Daurès

Authors
  1. Nicolas Flori
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Natalie Funakoshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yohan Duny
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jean-Christophe Valats
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Michael Bismuth
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Dimitri Christophorou
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jean-Pierre Daurès
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Pierre Blanc
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pierre Blanc.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Flori, N., Funakoshi, N., Duny, Y. et al. Pegylated Interferon-α2a and Ribavirin versus Pegylated Interferon-α2b and Ribavirin in Chronic Hepatitis C. Drugs 73, 263–277 (2013). https://doi.org/10.1007/s40265-013-0027-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-013-0027-1

Keywords

Search

Navigation